Bruix Jordi
BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBEREHD, Villarroel 170, Barcelona 08036, Spain.
Hepat Oncol. 2016 Aug;3(3):187-189. doi: 10.2217/hep-2016-0007. Epub 2016 Aug 19.
Dr Jordi Bruix is the Head of the Barcelona Clinic Liver Cancer (BCLC) group at the Hospital Clinic (University of Barcelona, Spain) and Director of the Network for Research in Liver and Digestive Disease (CIBEREHD) in the Spanish Research Institute. His research has changed the diagnosis and treatment of liver cancer. Major highlights include: development of the BCLC staging and treatment; development of diagnostic criteria for hepatocellular carcinoma; identification of the value of portal pressure in predicting prognosis after resection; and acting as principal investigator of the Phase III trials that have shown the benefits of chemoembolization, sorafenib and regorafenib for patients with liver cancer. He has authored the European Assoaciation for the Study of the Liver, American Association for the Study of Liver Diseases and World Gastroenterology Organization Practice Guidelines and the United Network for Organ Sharing hepatocellular carcinoma (HCC) diagnostic criteria.
霍尔迪·布鲁伊克斯博士是西班牙巴塞罗那大学附属医院临床医院巴塞罗那临床肝癌（BCLC）小组的负责人，也是西班牙研究所肝脏与消化系统疾病研究网络（CIBEREHD）的主任。他的研究改变了肝癌的诊断和治疗方式。主要成就包括：制定BCLC分期和治疗方案；制定肝细胞癌的诊断标准；确定门静脉压力在预测肝切除术后预后方面的价值；担任多项III期试验的主要研究者，这些试验证明了经动脉化疗栓塞、索拉非尼和瑞戈非尼对肝癌患者的疗效。他撰写了欧洲肝脏研究协会、美国肝病研究协会和世界胃肠病学组织的实践指南以及器官共享联合网络肝细胞癌（HCC）诊断标准。
